StreetInsider.com News Articles

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Thu, 03 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT.

NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York City taking place September 9-11, 2026.

The fireside chat will be webcast live on Friday, September

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Thu, 03 Sep 2026 07:30:00 -0400

CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT.

The fireside chat will be webcast live on Friday, September

Helus Pharma (HELP) PT Raised to $62 at TD Cowen

Thu, 20 Aug 2026 06:03:25 -0400

TD Cowen analyst Ritu Baral raised the price target on Helus Pharma (NASDAQ: HELP) to $62.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "We are raising our pNPV based target to $62 from $8 on three major recent value-creating tailwinds to our thesis: 1) increased visibility into Ph3 HLP003 adjunct MDD data timing, now expected mid-Nov 2026, 2) a new, seasoned CEO with an extensive operational and strategic track record in neuropsych, and 3) new M&A, regulatory and executive branch tailwinds for the psychedelic neuropsych sector."

Helus Pharma (HELP) PT Raised to $62 at TD Cowen

Thu, 20 Aug 2026 06:03:25 -0400

TD Cowen analyst Ritu Baral raised the price target on Helus Pharma (NASDAQ: HELP) to $62.00 (from $8.00) while maintaining a Buy rating.

Form D CYBIN INC.

Wed, 19 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260819/26950970.html

Form D CYBIN INC.

Wed, 19 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260819/26950970.html

Form D CYBIN INC.

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950943.html

Form D CYBIN INC.

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950943.html

H.C. Wainwright Reiterates Buy Rating on Helus Pharma (HELP)

Wed, 19 Aug 2026 06:48:57 -0400

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $70.00 price target on Helus Pharma (NASDAQ: HELP).

The analyst commented: "On August 14, Helus reported F1Q27 results and reiterated that enrollment in the Phase 3 trial (APPROACH) evaluating HLP003 in major depressive disorder (MDD) is complete, with topline data on track for 4Q26. APPROACH enrolled 223 adults with moderate-to-severe MDD who had an inadequate response to background antidepressant therapy. Two recent developments incrementally de-risk the program, in our view. First, a completed drug-drug interaction (DDI) study showed no meaningful pharmacokinetic (PK) interaction across the cytochrome P450 (CYP450) enzymes examined,

Form 6-K CYBIN INC. For: Aug 18

Wed, 19 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26946728.html

Form 6-K CYBIN INC. For: Aug 18

Wed, 19 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260819/26946728.html

Form 6-K CYBIN INC. For: Aug 18

Tue, 18 Aug 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260818/26942781.html

Form 6-K CYBIN INC. For: Aug 18

Tue, 18 Aug 2026 11:43:00 -0400

si-local-file:///var/storage/secattach/20260818/26942781.html

Helus Pharma names chief people officer, adds CNS expert to advisory board

Tue, 18 Aug 2026 07:30:17 -0400

Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) announced the appointment of Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board, according to a company statement.

Donohue previously served as Chief Human Resources Officer at Intra-Cellular Therapies, Inc., where she oversaw the company's human resources function as it grew to more than 1,000 employees and transitioned from a clinical to a commercial-stage organization. Intra-Cellular was acquired by Johnson & Johnson in April 2025. Earlier in her career, Donohue was among the first five executives hired to build LEO Pharma's U.S. subsidiary and also served as its

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

Tue, 18 Aug 2026 07:30:00 -0400

Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and commercialization

Ms. Donohue is the former Chief Human Resources Officer of Intra-Cellular, where she led the company’s people strategy and human resources infrastructure as it transitioned from a clinical to a commercial stage organization of 1,000+ employees

Dr. Durgam is a recognized CNS drug-development leader who played a pivotal role in securing multiple U.S. Food and Drug Administration (“FDA”) approvals for CAPLYTA® (lumateperone), including in schizophrenia, bipolar depression and adjunctive major depressive disorder

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

Tue, 18 Aug 2026 07:30:00 -0400

Form SCHEDULE 13G/A CYBIN INC. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26925184.html

Form SCHEDULE 13G/A CYBIN INC. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26925184.html

Form 6-K CYBIN INC. For: Aug 14

Fri, 14 Aug 2026 07:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26924634.html

Form 6-K CYBIN INC. For: Aug 14

Fri, 14 Aug 2026 07:44:00 -0400

si-local-file:///var/storage/secattach/20260814/26924634.html

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Fri, 14 Aug 2026 07:28:00 -0400

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 -

- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD -

- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -

- Continued participant rollover into

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Fri, 14 Aug 2026 07:28:00 -0400

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2   -

- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD -

- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -

- Continued participant rollover into

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Fri, 14 Aug 2026 07:28:00 -0400

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2   -

- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD -

- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -

- Continued participant rollover into

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Fri, 14 Aug 2026 07:28:00 -0400

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2   -

- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD -

- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -

- Continued participant rollover into

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Fri, 14 Aug 2026 07:28:00 -0400

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2   -

- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as a potential adjunctive treatment for MDD -

- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -

- Continued participant rollover into